Original Article| Volume 62, ISSUE 6, P652-657, September 15, 2007

N-Acetyl Cysteine, a Glutamate-Modulating Agent, in the Treatment of Pathological Gambling: A Pilot Study


      Although pathological gambling (PG) is relatively common, pharmacotherapy research for PG is limited. N-acetyl cysteine (NAC), an amino acid, seems to restore extracellular glutamate concentration in the nucleus accumbens and therefore offers promise in reducing addictive behavior.


      Twenty-seven subjects (12 women) with DSM-IV PG were treated in an 8-week open-label trial of NAC with responders (defined as a ≥ 30% reduction in Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling [PG-YBOCS] total score at end point) randomized to 6 weeks of double-blind NAC or placebo.


      The PG-YBOCS scores decreased from a mean of 20.3 ± 4.1 at baseline to 11.8 ± 9.8 at the end of the open-label phase (p < .001). Sixteen of 27 subjects (59.3%) met responder criteria. The mean effective dose of NAC was 1476.9 ± 311.3 mg/day. Of 16 responders, 13 entered the double-blind phase. Of those assigned to NAC, 83.3% still met responder criteria at the end of the double-blind phase, compared with only 28.6% of those assigned to placebo.


      The efficacy of NAC lends support to the hypothesis that pharmacological manipulation of the glutamate system might target core symptoms of reward-seeking addictive behaviors such as gambling. Larger, longer, placebo-controlled double-blind studies are warranted.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Argo T.A.
        • Black D.W.
        Clinical characteristics.
        in: Grant J.E. Potenza M.N. Pathological Gambling: A Clinical Guide to Treatment. American Psychiatric Publishing, Washington DC2004: 39-53
        • Baker D.A.
        • McFarland K.
        • Lake R.W.
        • Shen H.
        • Toda S.
        • Kalivas P.W.
        N-acetyl cysteine-induced blockade of cocaine-induced reinstatement.
        Ann N Y Acad Sci. 2003; 1003: 349-351
        • Carlsson M.L.
        On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder.
        Prog Neuropsychopharmacol Biol Psychiatry. 2001; 25: 5-26
        • Coric V.
        • Taskiran S.
        • Pittenger C.
        • Wasylink S.
        • Mathalon D.H.
        • Valentine G.
        • et al.
        Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial.
        Biol Psychiatry. 2005; 58: 424-428
        • Cunningham-Williams R.M.
        • Cottler L.B.
        • Compton III, W.M.
        • Spitznagel E.L.
        Taking chances: Problem gamblers and mental health disorders—results from the St. Louis Epidemiologic Catchment Area study.
        Am J Public Health. 1998; 88: 1093-1096
        • First M.B.
        • Spitzer R.L.
        • Gibbon M.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV-Patient Edition (SCID-I/P, Version 2.0).
        Biometrics Research Department, New York State Psychiatric Institute, New York1995
        • Frisch M.B.
        • Cornell J.
        • Villaneuva M.
        Clinical validation of the Quality of Life Inventory: A measure of life satisfaction for use in treatment planning and outcome assessment.
        Psychol Assess. 1993; 4: 92-101
        • Goldstein R.A.
        • Volkow N.D.
        Drug addiction and its underlying neurobiological basis: Neuroimaging evidence for the involvement of the frontal cortex.
        Am J Psychiatry. 2002; 159: 1642-1652
        • Grant J.E.
        • Kim S.W.
        Quality of life in kleptomania and pathological gambling.
        Compr Psychiatry. 2005; 46: 34-37
        • Grant J.E.
        • Levine L.
        • Kim D.
        • Potenza M.N.
        Impulse control disorders in adult psychiatric inpatients.
        Am J Psychiatry. 2005; 162: 2184-2188
        • Grant J.E.
        • Potenza M.N.
        Compulsive aspects of impulse control disorders.
        Psychiatr Clin North Am. 2006; 29: 539-551
      1. Grant JE, Potenza MN (in press): Treatments for Pathological Gambling and Other Impulse Control Disorders. In: Nathan PE, Gorman JM, editors. A Guide to Treatments that Work, 3rded. New York: Oxford University Press.

        • Grant J.E.
        • Potenza M.N.
        • Hollander E.
        • Cunningham-Williams R.
        • Nurminen T.
        • Smits G.
        • Kallio A.
        A multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling.
        Am J Psychiatry. 2006; 163: 303-312
        • Grant J.E.
        • Steinberg M.A.
        • Kim S.W.
        • Rounsaville B.J.
        • Potenza M.N.
        Preliminary validity and reliability testing of a structured clinical interview for pathological gambling (SCI-PG).
        Psychiatry Res. 2004; 128: 79-88
        • Guy W.
        ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76–338.
        in: National Institute of Mental Health, Rockville, Maryland1976: 218-222
        • Hamilton M.
        The assessment of anxiety states by rating.
        Br J Med Psychiatry. 1959; 32: 50-55
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Hemby S.E.
        • Tang W.
        • Muly E.C.
        • Kuhar M.J.
        • Howell L.
        • Mash D.C.
        Cocaine-induced alterations in nucleus accumbens ionotropic glutamate receptor subunits in human and non-human primates.
        J Neurochem. 2005; 95: 1785-1793
        • Hodgins D.C.
        • Petry N.M.
        Cognitive and behavioral treatments.
        in: Grant J.E. Potenza M.N. Pathological Gambling: A Clinical Guide to Treatment. American Psychiatric Publishing, Washington DC2004: 169-187
        • Hollander E.
        • DeCaria C.M.
        • Finkell J.N.
        • Begaz T.
        • Wong C.M.
        • Cartwright C.
        A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling.
        Biol Psychiatry. 2000; 47: 813-817
        • Hollander E.
        • Pallanti S.
        • Allen A.
        • Sood E.
        • Baldini Rossi N.
        Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?.
        Am J Psychiatry. 2005; 162: 137-145
        • Hollander E.
        • Pallanti S.
        • Baldini Rossi N.
        • Sood E.
        • Baker B.R.
        • Buchsbaum M.S.
        Imaging monetary reward in pathological gamblers.
        World J Biol Psychiatry. 2005; 6: 113-120
        • Kalivas P.W.
        • Volkow N.D.
        The neural basis of addiction: A pathology of motivation and choice.
        Am J Psychiatry. 2005; 162: 1403-1413
        • Kalivas P.W.
        • Volkow N.
        • Seamans J.
        Unmanageable motivation in addiction: A pathology in prefrontal–accumbens glutamate transmission.
        Neuron. 2005; 45: 647-650
        • Kim S.W.
        • Grant J.E.
        • Adson D.E.
        • Shin Y.C.
        Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling.
        Biol Psychiatry. 2001; 49: 914-921
        • Lafleur D.L.
        • Pittenger C.
        • Kelmendi B.
        • Gardner T.
        • Wasylink S.
        • Malison R.T.
        • et al.
        N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
        Psychopharmacol. 2006; 184: 254-256
        • LaRowe S.D.
        • Mardikian P.
        • Malcolm R.
        • Myrick H.
        • Kalivas P.
        • McFarland K.
        • et al.
        Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals.
        Am J Addict. 2006; 15: 105-110
        • Lochner C.
        • Hemmings S.M.J.
        • Kinnear C.J.
        • Niehaus D.J.H.
        • Nel D.G.
        • Corfield V.A.
        • et al.
        Cluster analysis of obsessive-compulsive spectrum disorders in patients with obsessive-compulsive disorder: Clinical and genetic correlates.
        Compr Psychiatry. 2005; 46: 14-19
        • McFarland K.
        • Lapish C.C.
        • Kalivas P.W.
        Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior.
        J Neurosci. 2003; 23: 3531-3537
        • Pallanti S.
        • DeCaria C.M.
        • Grant J.E.
        • Urpe M.
        • Hollander E.
        Reliability and validity of the Pathological Gambling Modification of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS).
        J Gambling Stud. 2005; 21: 431-443
        • Pasternak A.V.
        • Fleming M.F.
        Prevalence of gambling disorders in a primary care setting.
        Arch Fam Med. 1999; 8: 515-520
        • Peters J.
        • Kalivas P.W.
        The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats.
        Psychopharmacology (Berl). 2006; 186: 143-149
        • Potenza M.N.
        • Fiellin D.A.
        • Heninger G.R.
        • Rounsaville B.J.
        • Mazure C.M.
        Gambling: an addictive behavior with health and primary care implications.
        J Gen Intern Med. 2002; 17: 721-732
        • Rea L.M.
        • Parker R.A.
        Designing and Conducting Survey Research.
        Jossey-Bass Publishers, San Francisco1992
        • Robinson T.E.
        • Kolb B.
        Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine.
        J Neurosci. 1997; 17: 8491-8497
        • Shaffer H.J.
        • Hall M.N.
        • Vander Bilt J.
        Estimating the prevalence of disordered gambling behavior in the United States and Canada: A research synthesis.
        Am J Pub Health. 1999; 89: 1369-1376
        • Sheehan D.V.
        The Anxiety Disease.
        Scribner’s, New York1983